Gabor G. Illei

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis

Alan Kivitz, Liangwei Wang, Ilias Alevizos, Michele Gunsior et autres

OBJECTIVES: To evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid arthritis (RA). METHODS: This double-blind study included adult patients with moderate-to-severe active RA with a …

us (code pays fourni par la source)

Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis

Ahmad Akhgar, Dominic Sinibaldi, Lingmin Zeng, Alton B. Farris et autres

OBJECTIVE: Lupus nephritis (LN) is diagnosed by biopsy, but longitudinal monitoring assessment methods are needed. Here, in this preliminary and hypothesis-generating study, we evaluate the potential for using urine proteomics as a non-invasive method to monitor disease activity and damage. Urinary biomarkers …

us (code pays fourni par la source)

Feasibility and Safety of Obtaining Kidney Biopsy Research Cores in a Predominantly Black Lupus Nephritis Patient Population

Jason Cobb, Alton B. Farris, Ahmad Akhgar, Gabor G. Illei et autres

Background: Lupus nephritis (LN) occurs in >50% of patients with SLE. Black patients disproportionately suffer from LN with more severe disease. Histologic examination of kidney tissue is required for definitive diagnosis and advancing the science. We are reporting the feasibility and safety …

us (code pays fourni par la source)

circMTND5 Participates in Renal Mitochondrial Injury and Fibrosis by Sponging MIR6812 in Lupus Nephritis

Junjun Luan, Congcong Jiao, Cong Ma, Yixiao Zhang et autres

Recent studies have focused on nuclear‐encoded circular RNAs (circRNAs) in kidney diseases, but little is known about mitochondrial circRNAs. Differentially expressed circRNAs were analyzed by RNA deep sequencing from lupus nephritis (LN) biopsies and normal human kidneys. In LN renal biopsies, the …

cn, us (code pays fourni par la source)

Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus

Sencer Göklemez, Sarfaraz Hasni, Frances T. Hakim, Paolo A. Muraro et autres

OBJECTIVE: Autologous haematopoietic cell transplantation (AHSCT) improves immunologic dysfunction in patients with SLE. However, the curative potential of this therapy remains uncertain. This study reports outcomes in SLE patients receiving a lymphodepleting, reduced intensity regimen for AHSCT in SLE. METHODS: Eight patients …

in, us, gb (code pays fourni par la source)

Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus

Jodi L. Karnell, Yanping Wu, Nanette Mittereder, Michael A. Smith et autres

Plasmacytoid dendritic cells (pDCs) not only are specialized in their capacity to secrete large amounts of type I interferon (IFN) but also serve to enable both innate and adaptive immune responses through expression of additional proinflammatory cytokines, chemokines, and costimulatory molecules. Persistent …

us, gb, sg, pl (code pays fourni par la source)

Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus

Kerry A. Casey, Michael A. Smith, Dominic Sinibaldi, Nickie Seto et autres

OBJECTIVE: Neutrophil dysregulation and the type I interferon (IFN) axis have been proposed to contribute to premature cardiovascular disease, a leading cause of mortality in patients with systemic lupus erythematosus (SLE). In the present study, we evaluated the ability of anifrolumab, a …

us (code pays fourni par la source)

LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration

Junjun Luan, Jingqi Fu, Chengjie Chen, Congcong Jiao et autres

BACKGROUND: The prevalence of lupus nephritis (LN) remains high despite various emerging monoclonal antibodies against with targeting systemic lupus erythematosus (SLE). Renal fibrosis is the main feature of late stage LN, and novel therapeutic agents are still needed. We previously reported that …

cn, us (code pays fourni par la source)

Type I interferon gene signature test–low and –high patients with systemic lupus erythematosus have distinct gene expression signatures

PZ Brohawn, Katie Streicher, Brandon W. Higgs, Chris Morehouse et autres

Objectives Type I interferon (IFN) is implicated in systemic lupus erythematosus (SLE) pathogenesis. We aimed to identify type I IFN signaling-dependent and -independent molecular pathways in a large population of patients with SLE. Methods Baseline blood samples from adult patients with moderate …

us (code pays fourni par la source)

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Kerry A. Casey, Xiang Guo, Michael A. Smith, Shiliang Wang et autres

OBJECTIVE: κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe SLE, anifrolumab treatment demonstrated substantial reductions in multiple clinical endpoints. Here, we evaluated serum proteins …

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus

Joan T. Merrill, Richard Furie, Victoria P. Werth, Munther A. Khamashta et autres

OBJECTIVE: This post hoc analysis compared anifrolumab 300 mg every 4 weeks with placebo on rash and arthritis measures with different stringency in patients with moderate to severe SLE (phase IIb; MUSE; NCT01438489). Subgroups were analysed by type I interferon gene signature …

us, ae (code pays fourni par la source)

Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg

Eric F. Morand, Teodora Trasieva, Anna Berglind, Gabor G. Illei et autres

au, br, se, fr (code pays fourni par la source)